March 31, 2025 03:45 PM EDT
R&D
Cell/Gene Tx

Tenaya to lay off about one-third of staff, re­veals heart gene ther­a­py da­ta

Lei Lei Wu

News Reporter

Heart gene ther­a­py mak­er Tenaya Ther­a­peu­tics is lay­ing off 30% to 40% of its staff by the end of the year, the com­pa­ny’s CEO Faraz …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA will con­sol­i­date to five 'shared ser­vices of­fices,' ac­cord­ing to memo to Hill staffers

Roche plans Phase 3 for its lat­est Alzheimer’s drug at­tempt af­ter un­veil­ing more ear­ly da­ta

DOJ at­tor­ney says Boehringer In­gel­heim has 'tremen­dous lever­age' in IRA ne­go­ti­a­tions

FDA ap­proves Am­gen's Up­liz­na in IgG4-re­lat­ed dis­ease

Trump has tout­ed Right to Try as a life­saver. Sev­er­al gov­ern­ment staff sup­port­ing it were just let go

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times